Transcript Highlights:

• When I first started Syntex CBD, about 7% of people had even heard of CBD. Thank you, Ms. Corrigan.
• It is THC with a smidge of CBD.
• CBD and THC products, as well as for pain with our CBD topical creams.
• CBD retail concept.
• CBD oil, pure hemp-derived CBD oil gave me my life back. And I began sharing that with others.

Bills: HB 28, SB 3

Keywords: hemp regulation, consumable products, cannabinoids, state health, youth protection, licensing fees, criminal offenses, HB28, public testimony, committee decorum, bill substitute, legislative process

Summary: The meeting featured significant discussions regarding HB28, where the chair outlined the plans to bring forward a substitute for the bill. The chair emphasized the importance of maintaining order and decorum during the proceedings. Members engaged in deliberations, and a number of public witnesses were invited to testify, thereby enriching the discussion around the bill. This interaction provided valuable insights into public sentiment regarding the issues at hand.

Transcript Highlights:

• One is CBD.
• I guess I'm a little bit unsure if we know what CBD is.
• I don't think everybody understands what CBD is. CBD actually does not get you high.
• So I don't even know why we have any limits on CBD at all.
• brands, and I started taking CBD every day.

Bills: HF1545, HF2426, HF1615, HF2403

Keywords: medical cannabis, cultivation, cannabinoid products, plant canopy, Minnesota statutes, cannabis, hemp, lower-potency, edibles, regulations, licensing, local control, consumer safety, age restrictions, commerce policy, financial institutions, insurance regulation, limited long-term care insurance, Medicare supplement, health insurance

Transcript Highlights:

• CBD and CBG are safer.
• Mystery substances are harder to test for than I know this is a CBD tincture and I'm looking for CBD
• This one is CBD with some CBN.
• I will do CBD, CBG, and CBN.
• You're proposing CBD, CBG, and THC only.

Bills: HB28, SB3, SB 3

Keywords: hemp regulation, consumable products, cannabinoids, state health, youth protection, licensing fees, criminal offenses, flash flood, flood warning, outdoor warning siren, emergency alert, disaster preparedness, flood mitigation, Hill Country floods, Texas Water Development Board, municipalities, counties, local government mandate, public safety, grant program

Transcript Highlights:

• So, specifically, under SB 5, CBD and CBD-C, CBD-C, CBD-C, CBD-C, CBD-C, CBD-G will still be legal for
• No full spectrum products, CBD and CBG.
• CBD and CBG will still be legal.
• CBD is shown to affect the liver with long-term use.
• CBD and CBG can provide them that benefit.

Bills: SB5, SB11, SB12, SB9, SB42, SB15, SB5, SB11, SB12, SCR1

Keywords: hemp regulation, consumable products, cannabinoids, occupational licenses, criminal offenses, SB 11, Texas attorney general, election crimes, election law enforcement, criminal prosecution, Election Code, Government Code Chapter 402, local prosecutors, county attorney, district attorney, grand jury, probable cause reports, state election offenses, voter fraud, election integrity

Transcript Highlights:

• So it's not pure CBD? Not pure CBD, correct? Okay.
• In pure CBD, and in the market, you'll also see CBD isolates. That is extracted from the plant.
• We don't grow hemp biomass high in CBD for CBD products. It's CBDA.
• It looks like it actually comes from CBD. I mean, it is, it can be converted from CBD.
• synthetic compounds in CBD.

Summary: The House Committee on Public Health heard House Bill 5, a proposal to ban THC products outside the Texas Compassionate Use Program while allowing non-intoxicating CBD and CBG products under tighter regulation. Chair Van Deaver gave a lengthy background on the 2018 federal Farm Bill and Texas’s 2019 hemp law, arguing that the lack of guardrails allowed a large, unregulated THC market to develop. HB 5 would impose licensing fees, product registration, testing and inspection requirements, and restrictions intended to keep products away from children. Invited witnesses from law enforcement strongly supported the bill. Steve Dye of the Texas Police Chiefs Association and Brian Hawthorne of the Sheriffs’ Association of Texas argued that THC consumables are widely mislabeled, often far more potent than advertised, and linked to youth access, impaired driving, and organized crime. Both said regulation would be ineffective and would amount to legalization, while a ban would be easier for officers to enforce. They also emphasized support for the Texas Compassionate Use Program and said medical THC should remain available. Dr. Peter Stout of the Texas Association of Crime Lab Directors and Alice Amelot of Texas DPS testified as resource witnesses about forensic testing. They said current lab resources are already stretched thin, that quantitative testing for THC and related cannabinoids is expensive and time-consuming, and that a ban would simplify enforcement because labs could focus on presence/absence testing rather than concentration. Amelot said DPS labs are neutral on the bill but explained that mislabeled products and inaccurate certificates of analysis are common. Committee members asked about traffic safety, impairment, youth use, and the costs of enforcement and lab testing; witnesses repeatedly said the bill would reduce complexity for law enforcement but that any approach would still require more resources for labs.

Transcript Highlights:

• a CBD-THC ratio version.
• So equal parts THC and CBD.
• a CBD-THC ratio version.
• So equal parts THC and CBD.
• a CBD-THC ratio version.

Keywords: 1191, senate, all

Transcript Highlights:

• So, it's not pure CBD? Pure CBD, correct? Okay. I think this makes sense.
• Grade CBD biomass.
• It's CBD. During the processing, it's processed into CBD.
• If I were to deliver a hemp product for CBD extraction, it's not even CBD.
• It looks like it actually comes from CBD, I mean, it can be converted from CBD. Right?

Bills: HB5

Keywords: hemp, cannabinoids, regulation, occupational licenses, consumable products, marketing, criminal offenses, labeling requirements, health and safety, 997, house, all

Transcript Highlights:

• In 2002, a chemist filed a patent for converting CBD oil into Delta-9 THC.
• What that does, in effect, is mean none of the CBD products or none of the CBD shops will be touched;
• And I think there's a lot of CBD shops that are very, very... ...the smell of it.
• level total THC level such as CBD and does not disrupt the CBD and that very low intoxicating total
• And H-179, this is the one that's focused on CBD in hemp.

Keywords: 995, all

Summary: The Joint Committee on Cannabis Policy held a hearing on a broad set of cannabis and hemp bills, with the chairs opening by emphasizing unfinished work on equity, public health, safety, and market stability. The committee heard testimony on House Bill 146, which would create more efficient cannabis testing standards by increasing batch sizes, reducing or eliminating some environmental testing, standardizing lab reporting, and requiring annual scientific review and public data reporting. Industry witnesses, including a representative of the Massachusetts Cannabis Coalition, cultivators, and a testing lab owner, said current testing rules are overly burdensome, costly, and inconsistent, and argued the bill would lower compliance costs while preserving consumer safety. A testing lab witness also said some operators switch labs to obtain higher THC results or pass contaminated batches, and urged greater transparency and better sampling protocols. A major portion of the hearing focused on intoxicating hemp and related bills that would bring hemp-derived intoxicating products under a stronger regulatory framework. Legislators and industry witnesses described products sold in gas stations, smoke shops, and convenience stores as often untested, not age-gated, and sometimes mislabeled or far above the federal hemp THC threshold. Testimony from attorneys and cannabis business leaders said states can regulate these products more strictly under the Farm Bill’s non-preemption language, and pointed to New Jersey and other states as possible models. Some witnesses and committee members stressed that any new rules should avoid harming non-intoxicating CBD businesses or lawful hemp farmers, while others argued that the products are effectively cannabis and should be regulated like cannabis for licensing, testing, age limits, and taxation. The committee also heard extensive public-health testimony in support of bills S. 95, S. 96, S. 97 and their House counterparts H. 191, H. 192, and H. 193. Parents, advocates, and public health professionals urged stronger warning labels, THC potency caps, and improved data collection on cannabis-related harms, citing cannabis-induced psychosis, addiction, anxiety, and youth exposure to high-potency products. Several witnesses said Massachusetts has not done enough to track health outcomes or warn consumers, and referenced other jurisdictions such as Connecticut, Vermont, Colorado, Canada, and Quebec as examples of stronger limits or warnings. No votes or formal actions were taken during the hearing; the committee primarily received testimony and questions.

Transcript Highlights:

• and CBD-ratio products.
• and CBD-ratio products.
• and CBD-ratio products.
• , CBD-ratio products.
• and CBD-ratio products.

Keywords: 1189, house, all

Transcript Highlights:

• Nowadays, we're were richer in CBD.
• There are CBD oil similar products.
• , because the overwhelming amount of CBD, because the overwhelming amount of CBD, which<00:52:32.319
• of turn here but there are some 250 CBD of turn here but there are some 250 CBD medical<01:02:03.359
• So, we've heard from CBD helps them."

Keywords: 1189, house, all

Transcript Highlights:

• We also do contract manufacturing, where we use our own in-house CBD ingredients to make CBD products
• Hawaii CBD in their products.
• who wish to use uh high quality hoy CBD who wish to use uh high quality hoy CBD uh<01:41:37.199>
• > CBD<01:41:44.400> tinctures, lines that include CBD tinctures, lines that include CBD
• where if we are to create a CBD where if we are to create a CBD ingredient<01:43:59.600> and<

Bills: HB1974, HB1853, HB1973, HB1574, HB2619, HB1966, HB1643, HB1671, HB2558, HB1854, HB2173, HB1575, HB2229, HB1535, HB1978, HB2508, HB1549, HB2187, HB1550, HB1977, HB2314, HB1871, HB2319, HB1591, HB1858, HB1898, HB2372, HB1765, HB2012, HB1706, HB1962, HB1963, HB1975, HB2009, HB2083, HB2224, HB1877, HB1959, HB1626, HB1665, HB2488, HB2456, HB2548, HB2207, HB1832, HB2079, HB1985, HB1618, HB2486, HB2242, HB2045, HB1703, HB2236, HB2480, HB1976, HB2287, HB2288, HB1777, HB276, HB1660, HB1676, HB1605, HB1751, HB1967, HB2383, HB2340, HB1946, HB2268, HB1950, HB2156, HB2118, HB1859, HB1863, HB1996, HB2114, HB2423, HB2429, HB2475, HB2534, HB2545, HB1813, HB1941, HB2474, HB2583, HB1576, HB1886, HB1939, HB2540, HB2590, HB2000, HB2163, HB2386, HB1691, HB1680, HB2516, HB1993, HB2442, HB1510, HB1958, HB1692

Keywords: HB1974, hearing loss, audiology, audiologist, hearing screening, hearing aids, cochlear implants, tele-audiology, communication access, assistive technology, speech-language pathology, deafness, hard of hearing, public health, kupuna, keiki, dementia, cognitive decline, fall prevention, State Health Planning and Development Agency

Transcript Highlights:

• :32:08.080> see different Fashions the CBD that you see different Fashions the CBD that you see
• CBD has some relationship between CBD and hemp, yeah.
• percentages of THC they still have CBD percentages of THC they still have CBD in<01:47:09.560>
• and a lot of people find um you know CBD and a lot of people find um you know CBD is<01:47:48.960
• hemp production has not regulated CBD hemp production has not regulated CBD markets<01:59:54.280

Keywords: 1189, house, all

Transcript Highlights:

• I represent the largest brick-and-mortar CBD... represent the largest brick-and-mortar CBD franchise
• of Healthy Harvest CBD.
• The CBD products you sell, are they the true hemp CBD products or are these delta 8, delta 9?
• I own three CBD stores, SunMed.
• We're the largest brick-and-mortar CBD retailer in the world right now.

Keywords: 923, senate, all

Transcript Highlights:

• Will CBD or CBG be full spectrum?
• FDA studies have shown that CBD can cause liver damage and, in men, CBD can cause testicular problems
• Epidiolex is an FDA-approved CBD prescription.
• CBD and CBG are specifically legal in this bill.
• You have to pull the CBD away from the THC.

Bills: SB 5, SB 11, SB 12

Keywords: disaster relief, flood preparedness, emergency funding, local government support, meteorological forecasting, human trafficking, trafficking victim, compelling prostitution, affirmative defense, criminal defense, coercion, force fraud or coercion, sexual exploitation, victim protection, Penal Code, Texas criminal law, prosecution, party liability, affirmative defense statute, survivor rights

Summary: The Senate Committee on State Affairs took up Senate Bill 5, which Senator Perry described as a ban on intoxicating THC consumer products while preserving legal CBD, CBG, hemp seed, hemp seed protein powder, and hemp seed oil products. Perry argued that most retail THC products are already illegal under federal law, that the industry has used loopholes and misleading labeling to sell high-potency products, and that regulation would be ineffective because chemists can quickly alter formulations. He also said the bill would steer people with medical needs toward the Texas Compassionate Use Program (T-Cup), which he and other supporters described as the proper physician-guided alternative. Committee members and witnesses repeatedly discussed the distinction between legal hemp-derived products and intoxicating THC products, and Perry said the bill would not touch non-consumable hemp uses such as fiber and clothing. Invited testimony came from law enforcement and medical witnesses who supported the bill. Texas Police Chiefs Association representative Steve Dye, Kaufman County District Attorney Early Wiley, and Chambers County Sheriff Brian Hawthorne all said regulation would be too costly, too complex, and ultimately unenforceable, while a ban would be clearer and easier to enforce. They cited overloaded DPS labs, the need for expensive private testing, limited police and prosecutor resources, and the difficulty of keeping up with constantly changing cannabinoids and out-of-state products. Hawthorne and Wiley described raids and investigations involving warehouses, retail stores, cash seizures, and products they said were marketed to young people and often mislabeled or imported from other states. They also said the bill would help law enforcement by creating a clearer legal line and protecting legitimate CBD/CBG businesses. Dr. Lindy McGee, speaking for the Texas Medical Association and Texas Pediatric Society, testified that retail THC products pose serious risks to children and adolescents, including addiction, impaired brain development, psychosis, suicide attempts, self-harm, accidental toddler ingestions, and possible long-term cognitive effects. She said there is no effective medication treatment for THC addiction comparable to nicotine cessation tools, and she supported restrictions such as child-resistant packaging, no marketing to minors, and age limits, while opposing criminal penalties for possession by minors. Senators asked follow-up questions about brain development, memory, dementia risk, pregnancy, and cardiovascular effects. No vote was taken during the portion provided, and the committee continued with invited testimony and questions.

Transcript Highlights:

• I get the question: does CBD or CBG get you high?
• FDA studies have shown that CBD can cause liver damage and, in many cases, CBD can cause testicular problems
• Epidiolex is an FDA-approved CBD prescription. If a person under 21 needs CBD, they can.
• Is it CBD, CBG at that point? So, there are a few different flower options, like there's CBD.
• You have to pull the CBD. away from the THC.

Bills: SB5, SB11, SB12, SB 5, SB 11, SB 12

Keywords: hemp regulation, consumable products, cannabinoids, occupational licenses, criminal offenses, SB 11, Texas attorney general, election crimes, election law enforcement, criminal prosecution, Election Code, Government Code Chapter 402, local prosecutors, county attorney, district attorney, grand jury, probable cause reports, state election offenses, voter fraud, election integrity

Transcript Highlights:

• actions on the hemp industry, especially pertaining to the cultivation and processing manufacture of CBD
• <00:02:12.480> products processing manufacturer of CBD products processing manufacturer of
• However, I have a lot of concerns about we already have a problem with the CBD purveyors and the effect
• c><00:03:02.000> problem<00:03:02.239> with<00:03:02.400> the<00:03:02.640> CBD
• we already have a problem with the CBD we already have a problem with the CBD purveyors<00:03:03.760

Bills: SB3275

Keywords: cannabis, low-dose, personal use, cultivation, cannabis accessories, Hawaii cannabis law, medical cannabis, 912, senate, all

Summary: The Senate Committee on Commerce and Consumer Protection met in decision-making on SB 2760, which had previously been heard jointly with the Agriculture and the Environment Committee. The committee recommended passage with amendments, including language authorizing suspension of certain regulations as needed to enable quarantine treatments and changing the effective date. No members objected, and the recommendation was adopted by unanimous aye votes from the chair, vice chair, and other senators present. The committee then reconvened on SB 3275 relating to cannabis. The chair explained the bill was being kept moving so the Legislature could continue discussing the impacts of recent federal actions on the hemp industry, especially cultivation and processing of CBD products in Hawaii. The proposed amendments would strike several sections and pages of the bill, remove references to the Department of Commerce and Consumer Affairs, and substitute the Office of Medical Cannabis Control and Regulation, along with technical non-substantive changes. During discussion, several senators raised concerns about CBD purveyors and the effect on the 329 program, and noted constituent communications on both sides of the issue. One senator said they would vote with reservations, and others said they would vote no. Despite the concerns, the committee voted to pass SB 3275 with amendments, and the recommendation was adopted.

Transcript Highlights:

• CBD products, natural CBD products, meaning they have not been chemically altered with synthetics or.
• That's CBD. This is about THC.
• That's all CBD... That's all CBD, everything, so we can't separate out drinks or whatnot.
• It has CBD and THC components in it.
• What ends up happening, you guys, is that the CBD products that Mr.

Keywords: 977, all

Transcript Highlights:

• Well, I think what this law does is, like legitimate hemp, like CBD, is very popular.
• The unlicensed retailers will also often code these products as other or CBD.
• CBD with 0.3 THC—how does that bottle go to be the things that you sell?
• Full-spectrum CBD, by definition, contained THC.
• It was that strain of hemp at CBD, that full-spectrum CBD, that returned her quality of life and allowed

Keywords: 959, house, all

Transcript Highlights:

• If they could outsource that, CBD is legal federally, they could include CBD in their products at a much
• If they could outsource that, CBD is legal federally, they could include CBD in their products at a much
• If they could outsource that, CBD is legal federally, they could include CBD in their products at a much
• If they could outsource that, CBD is legal federally, they could include CBD in their products at a much
• <01:11:52.600> is if they could Outsource that uh CBD is if they could Outsource that uh CBD

Keywords: 928, house, all

Summary: The Health and Human Services Oversight Committee met on February 2 and first approved the draft minutes from the prior meeting, with minor corrections to the meeting date and attendance notation. DHHS Associate Commissioner Patricia Tilly then gave a department update, describing the current uncertainty around federal priorities and funding, and provided two substantive reports: progress on the new Hampstead Youth Development Center and an update on the department’s review of an ALS registry proposal. She said the YDC project is underway with tree clearing, fencing, stormwater and site-prep work, and remains on track for completion by June 30, 2026 and operation by August 30, 2026. The center currently has 12 youth, and the new design is intended to provide flexibility for fluctuating census levels. On ALS, Tilly explained that HB 576 had prompted the department to examine whether a registry could be built, but the estimated cost of a HIPAA-compliant system was about $750,000. She said DHHS is reviewing whether existing data sources, such as hospital discharge data and CHIS claims data, could provide useful information, but noted both are incomplete for registry purposes. Committee members discussed whether the Rare Disease Advisory Council, Dartmouth, or existing cancer registry infrastructure could help reduce costs. DHHS said it is neutral and willing to continue exploring alternatives, while members emphasized the value of a registry and the need to consider shared infrastructure and funding. The committee also heard from Jenny Horan of the Alzheimer’s Association, who presented the subcommittee’s report on Alzheimer’s disease and related dementias. She said the subcommittee spent the past year gathering information on dementia care, abuse and exploitation issues, caregiver strain, and available services, and is now moving into a second phase focused on identifying gaps and developing a state plan. Members asked about geriatric psychiatric capacity and long-term care availability; Horan said the state has limited capacity and that the plan will help clarify where needs are greatest. She offered to return for follow-up questions at a later meeting. Finally, Olivia May of DHHS presented the quarterly report on the 12-month postpartum Medicaid coverage extension. She said New Hampshire implemented the extension after federal and state action, and the first claims data are still emerging because of reporting lags. In the initial cohort studied, 95% received some medical services during the extended period, 52.4% received mental health or substance use disorder treatment, 26.7% received preventive visits, and 3.2% received heart or hypertension services. Members asked about return on investment and whether higher federal matching rates are being used appropriately; DHHS said it claims the highest possible match based on eligibility group and will return with more data over time. The committee then heard the annual therapeutic cannabis program report from Michael Holt, who said the program had 1,475 registered patients as of June 30, 2024 and that growth has slowed, with New Hampshire having the lowest per-capita medical cannabis enrollment nationally.

Transcript Highlights:

• to cover uh certain costs related to CBD to cover uh certain costs related to CBD and<00:33:13.039
• <00:35:33.839> Um, are from CBD. Um, are from CBD.
• CBD products, right? what that means. CBD products, right?
• , hemp, but it's basically just CBD, hemp, but it's basically just CBD, right?
• CBD with extremely low trace right?

Keywords: 912, senate, all

Summary: The committee first heard SB 888, which would bar operators of smart household security devices from sharing user data with law enforcement unless the user consents or police obtain a warrant. DCCA’s Office of Consumer Protection offered comments and Judiciary submitted written support. Several individuals also submitted written support. The committee recommended passage with amendments clarifying that the Office of Consumer Protection may enforce violations and adopting Judiciary’s recommended changes, while also deferring the effective date to July 1, 2050. The motion passed unanimously among members present, with one senator excused. The committee then took up SB 2777 on insurance disclosures. The bill would require authorized insurers to disclose claim-handling data to consumers, including claims open at the start of a period, closed with payment, closed without payment, and open at the end of the period. The committee described amendments to clarify the bill, remove a requirement for the DCCA insurance division to handle publication, and defer the effective date to July 1, 2050. The measure was passed with amendments and the recommendation was adopted, with one member voting no and another excused. In a joint Commerce and Consumer Protection/Judiciary hearing on SP2738 relating to tax haven abuse, the Department of Taxation offered comments and the Tax Foundation testified in opposition, arguing the state should rely on IRS audits and existing worldwide reporting rules rather than create a separate state approach. Other written testimony was noted in both support and opposition. The committees recommended passage with amendments adopting Taxation’s technical changes and deferring the effective date to July 1, 2050; the recommendation was adopted, with one senator noting reservations. The joint hearing then moved to health-related bills, including SB 2690 on primary care spending, SB 3103 on energy assistance, SB 3137 on Department of Health authority over food, drugs, and cosmetics, SB 3164 on child welfare service organizations, and SB 3206 on cannabinoids. SB 2690 drew strong support from physicians and advocates who said it would address primary care shortages, especially on neighbor islands, while HMSA and others warned a fixed spending percentage could raise costs and suggested a working group. SB 3164 drew support from child welfare providers and opposition from the Attorney General over indemnification language, and SB 3206 drew mixed testimony: state agencies raised federal-law and vagueness concerns, while hemp and cannabis advocates and some farmers supported the measure and urged broader legalization or amendments.